BIOLIFE SOLUTIONS INC (BLFS)
US09062W2044 - Common Stock
BLFS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BLFS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BLFS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLFS had negative earnings in the past year.
BLFS had a negative operating cash flow in the past year.
BLFS had negative earnings in 4 of the past 5 years.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -16.09%, BLFS is doing worse than 63.79% of the companies in the same industry.
The Return On Equity of BLFS (-19.67%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.09% | ||
| ROE | -19.67% | ||
| ROIC | N/A |
ROA(3y)-16.25%
ROA(5y)-9.96%
ROE(3y)-19.97%
ROE(5y)-12.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of BLFS (32.63%) is worse than 68.97% of its industry peers.
In the last couple of years the Gross Margin of BLFS has declined.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.95%
GM growth 5Y-13.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLFS has more shares outstanding
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
Compared to 1 year ago, BLFS has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.60 indicates that BLFS is not in any danger for bankruptcy at the moment.
BLFS has a Altman-Z score of 5.60. This is in the better half of the industry: BLFS outperforms 75.86% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that BLFS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.06, BLFS is in line with its industry, outperforming 58.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.6 |
ROIC/WACCN/A
WACC12.31%
2.3 Liquidity
BLFS has a Current Ratio of 2.86. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS has a Current ratio of 2.86. This is comparable to the rest of the industry: BLFS outperforms 56.90% of its industry peers.
A Quick Ratio of 1.83 indicates that BLFS should not have too much problems paying its short term obligations.
The Quick ratio of BLFS (1.83) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.57% over the past year.
Looking at the last year, BLFS shows a very negative growth in Revenue. The Revenue has decreased by -11.43% in the last year.
BLFS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.71% yearly.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q73.91%
Revenue 1Y (TTM)-11.43%
Revenue growth 3Y43.88%
Revenue growth 5Y48.71%
Revenue growth Q2Q-26.04%
3.2 Future
Based on estimates for the next years, BLFS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.33% on average per year.
Based on estimates for the next years, BLFS will show a quite strong growth in Revenue. The Revenue will grow by 13.85% on average per year.
EPS Next Y9.35%
EPS Next 2Y21.15%
EPS Next 3Y23.33%
EPS Next 5YN/A
Revenue Next Year-22.22%
Revenue Next 2Y-3.9%
Revenue Next 3Y-0.85%
Revenue Next 5Y13.85%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BLFS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLFS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BLFS's earnings are expected to grow with 23.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.15%
EPS Next 3Y23.33%
5. Dividend
5.1 Amount
BLFS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOLIFE SOLUTIONS INC
NASDAQ:BLFS (5/3/2024, 7:00:01 PM)
After market: 18.03 0 (0%)18.03
-0.13 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap816.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.09% | ||
| ROE | -19.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.86 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-11.43%
Revenue growth 3Y43.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y